Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors

A compound, C1-C3 technology, applied in the field of substituted pyridopyrimidine compounds and their use as FLT3 inhibitors, which can solve problems such as expression

Active Publication Date: 2015-03-18
OSCOTEC INC
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, MER is not expressed in normal lymphocytes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors
  • Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors
  • Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0111] The following examples illustrate the preparation of the compounds of formula (I) of the present invention and further illustrate the present invention by these examples. The examples are for illustrative purposes only and are not intended and should not be construed as limiting the invention in any way. Those skilled in the art will recognize that changes and modifications can be made without altering the scope of the invention.

[0112] Liquid chromatography-mass spectrometry (LC-MS) method:

[0113] 1. The sample was run at a flow rate of 1.5 mL / min on an Agilent Technologies 6120 MSD system with a Zorbax Eclipse XDB-C18 (3.5 μ) inverted column (4.6×50 mm) running at room temperature.

[0114] 2. The mobile phase uses solvent A (water / 0.1% formic acid) and solvent B (acetonitrile / 0.1% formic acid): 95% / 5% to 0% / 100% (A / B) for 5 minutes.

[0115] 3. Record mass spectra (m / z) using electrospray ionization (ESI).

[0116] 4. Ionization data is rounded to the nearest ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

Description

[0001] related application [0002] This application claims the benefit of and priority to US Provisional Patent Application No. 61 / 614,274, filed March 22, 2012, which is hereby incorporated by reference in its entirety. Background of the invention [0003] FLT3 (FMS-like tyrosine kinase 3, also known as Flk2) is a member of the type III receptor tyrosine kinase (RTK) family and plays an important role in the proliferation and differentiation of hematopoietic stem cells. Activating mutations and overexpression of this receptor are found in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mastocytosis, and gastrointestinal stromal tumors (GIST). In addition to activating mutations, autocrine or paracrine ligand stimulation by overexpressing wild-type FLT3 can lead to malignant phenotypes. [0004] Ligands for FLT3 are expressed by bone marrow stromal cells and other cells and potentiated synergistically with other growth factors to stimulate the proliferation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D471/04A61K31/519A61P35/00
CPCC07D239/00C07D471/04A61K31/31A61K31/519C07D487/04A61K45/06A61P25/00A61P25/28A61P35/00A61P35/02A61P37/02A61P37/06
Inventor 金宏宇李希奎宋浩俊李宰奎高钟盛金政浩金世园李任勇
Owner OSCOTEC INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap